Kazimierz Groen

Kazimierz Groen

Auto-generated profile, based on publicly available information

Kazimierz Groen

Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in HemaSphere
Verified
Journal Article
Open access
CKCharlotte L. B. M. Korst
Charlotte L. B. M. Korst
KGKaz Groen
Kaz Groen
PBPatricia W. C. Bosman
Patricia W. C. Bosman
FVFleur van der Valk
Fleur van der Valk
CVChristie P. M. Verkleij
Christie P. M. Verkleij
NDNiels W.C.J. Van De Donk
Niels W.C.J. Van De Donk

19 October 2023 in International Journal of Medical Informatics
Verified
Journal Article
Open access
EKEva S. Klappe
Eva S. Klappe
JHJarom Heijmans
Jarom Heijmans
KGKaz Groen
Kaz Groen
JSJudith ter Schure
Judith ter Schure
RCRonald Cornet
Ronald Cornet
NKNicolette F. de Keizer
Nicolette F. de Keizer
Correctly structured problem lists in electronic health records (EHRs) offer major benefits to patient care. Without structured lists, diagnosis information is often scatteredly documented in free text, which may contribute to errors and inefficient information retrieval. This study aims to assess whether EHRs with correctly structured problem lists result in better and faster clinical decision-making compared to non-curated problem lists. Two versions of two patient records (A and B) were created in an EHR training environment: one version included diagnosis information structured and coded on the problem list ("correctly structured problem list"), the other version had missing problem list diagnoses and diagnosis information partly documented in free text ("non-curated problem list"). In this single-blinded crossover randomized controlled trial, healthcare providers, who can prescribe medications, from two Dutch university medical center locations first evaluated a randomized version of patient A, then B. Participants were asked to motivate their answer to two medication prescription questions. One (test) question required information similarly presented in both record versions. The second (comparison) question required information documented on problem lists and/or in notes. The primary outcome measure was the correctness of the motivated answer to the comparison question. Secondary outcome measure was the time to answer and motivate both questions correctly. As planned, 160 participants enrolled. Two were excluded for not meeting inclusion criteria. Correctly structured problem lists increased providers' ability to answer the comparison question correctly (56.3 % versus 33.5 %, McNemar odds ratio 2.80 (1.65-4.93) 95 %-CI). Median time to answer both questions correctly was significantly lower for EHRs with correctly structured problem lists (Wilcoxon-signed-rank test p = 0.00002, with incorrect answers coded equally at slowest time). Correctly structured problem lists lead to better and faster clinical decision-making. Increased structured problem lists usage may be warranted for which implementation policies should be developed.

28 August 2023 in eClinicalMedicine
Verified
Journal Article
Open access
KGKaz Groen
Kaz Groen
CSClaudia A.M. Stege
Claudia A.M. Stege
KNKazem Nasserinejad
Kazem Nasserinejad
KHKoen de Heer
Koen de Heer
RKRoel J.W. van Kampen
Roel J.W. van Kampen
SZSonja Zweegman
Sonja Zweegman
The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients. In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years. The primary endpoint was overall response rate on induction treatment. Patients were included from October 2017 until May 2019. Trial Registration Number: NTR6297. Sixty-five patients were included. Induction therapy resulted in an overall response rate of 71%. Early mortality was 1.5%. At a median follow-up of 41.0 months, median progression-free survival (PFS) was 18.2 months and 3-year overall survival 83%. Discontinuation of therapy occurred in 77% of patients, 49% due to progression, 9% due to toxicity, 8% due to incompliance, 3% due to sudden death and 8% due to other reasons. Dose modifications of ixazomib were required frequently (37% and 53% of patients during induction and maintenance, respectively), mainly due to, often low grade, polyneuropathy. During maintenance 23% of patients received daratumumab alone. Global quality of life (QoL) improved significantly and was clinically relevant, which persisted during maintenance treatment. Ixazomib-Daratumumab-low-dose dexamethasone as first line treatment in intermediate-fit NDMM patients is safe and improves global QoL. However, efficacy was limited, partly explained by ixazomib-induced toxicity, hampering long term tolerability of this 3-drug regimen. This highlights the need for more efficacious and tolerable regimens improving the outcome in vulnerable intermediate-fit patients. 10.13039/100008897 Janssen Pharmaceuticals , Takeda Pharmaceutical Company Limited.

4 July 2024 in HemaSphere
Verified
Journal Article
Open access
KGKazimierz Groen
Kazimierz Groen
FSFebe Smits
Febe Smits
KNKazem Nasserinejad
Kazem Nasserinejad
MLMark‐David Levin
Mark‐David Levin
JRJosien C. Regelink
Josien C. Regelink
SZSonja Zweegman
Sonja Zweegman

5 October 2025 in HemaSphere
Verified
Journal Article
Open access
WBWassilis S. C. Bruins
Wassilis S. C. Bruins
FSFebe Smits
Febe Smits
CDCarolien Duetz
Carolien Duetz
KNKazem Nasserinejad
Kazem Nasserinejad
KGKazimierz Groen
Kazimierz Groen
Tuna MutisTuna Mutis
Tuna Mutis
The treatment landscape for older patients with multiple myeloma (MM) has rapidly evolved with the introduction of CD38‐targeting antibodies. Yet, outcomes remain highly variable and are only partially explained by frailty status. To address this, we investigated the impact of the immune system on survival outcomes of 89 newly diagnosed MM patients in the HOVON‐143 trial, where frail or intermediate‐fit patients received daratumumab–ixazomib–dexamethasone. Comprehensive immunophenotyping of lymphoid and myeloid subsets as relative or absolute counts in peripheral blood (PB) and bone marrow revealed comparable immune composition between frail and intermediate‐fit patients at diagnosis, except for reduced naive CD4 + and CD8 + T‐cells and increased effector memory CD4 + T‐cells and CD56 bright NK‐cells in frail patients. Among 36 T‐cell and NK‐cell subsets analyzed, 9 subsets—measured as absolute counts in PB—showed strong association with progression‐free survival (PFS) and 5 with overall survival (OS). Four subsets were linked to both PFS and OS: higher absolute counts of naive CD8 + T‐cells, CD38 + CD4 + T‐cells, and CD56 dim CD57 + NK‐cells were associated with longer survival, whereas elevated EM CD8 + T‐cell counts were linked to shorter survival. Using the most predictive immune parameters, we subsequently developed two immune risk scores—one for PFS and one for OS—which remained strongly associated with survival after adjusting for frailty status, disease stage, and cytogenetic risk. Our findings underscore the importance of a composite analysis of the immune system and demonstrate the association of baseline immune parameters with survival outcomes of first‐line therapy in non‐fit MM patients.

8 December 2025 in HemaSphere
Verified
Journal Article
Open access
KGKazimierz Groen
Kazimierz Groen
FSFebe Smits
Febe Smits
KNKazem Nasserinejad
Kazem Nasserinejad
MLMark‐David Levin
Mark‐David Levin
JRJosien C. Regelink
Josien C. Regelink
SZSonja Zweegman
Sonja Zweegman